Hence, in this context, targeting of EGFR-positive BRAFi-resistant CM cells by combined treatment with cetuximab and ICIs might appear an extremely attractive option that would take advantage of the concomitant action on tumor and immune cells. The gene discussed is EGFR; the disease is neoplasm.